Xeris Biopharma Holdings, Inc. (FRA:2B30)
Germany · Delayed Price · Currency is EUR 6.12
+0.02 (0.33%)
At close: Nov 28, 2025
Xeris Biopharma Holdings Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| 266.14 | 203.07 | 163.91 | 110.25 | 49.59 | 20.44 | Upgrade | |
Revenue Growth (YoY) | 42.05% | 23.89% | 48.68% | 122.32% | 142.67% | 650.74% | Upgrade |
Cost of Revenue | 41.1 | 36.83 | 28.65 | 22.63 | 13.32 | 9.33 | Upgrade |
Gross Profit | 225.04 | 166.24 | 135.27 | 87.61 | 36.27 | 11.11 | Upgrade |
Selling, General & Admin | 168.91 | 157.38 | 146.1 | 137.75 | 116.06 | 73.73 | Upgrade |
Research & Development | 29.38 | 25.56 | 22.34 | 20.97 | 25.16 | 18.92 | Upgrade |
Amortization of Goodwill & Intangibles | 10.84 | 10.84 | 10.84 | 10.84 | 0.55 | - | Upgrade |
Operating Expenses | 209.14 | 193.78 | 179.28 | 169.55 | 141.77 | 92.65 | Upgrade |
Operating Income | 15.9 | -27.55 | -44.01 | -81.94 | -105.5 | -81.55 | Upgrade |
Interest Expense | -29.63 | -30.49 | -26.61 | -14.1 | -7.18 | -10.66 | Upgrade |
Interest & Investment Income | 4.19 | 5.32 | 4.75 | 2.58 | 0.73 | 1.47 | Upgrade |
Other Non Operating Income (Expenses) | 0 | 0.01 | 0 | 1.76 | -0.7 | -0.01 | Upgrade |
EBT Excluding Unusual Items | -9.54 | -52.7 | -65.87 | -91.7 | -112.66 | -90.75 | Upgrade |
Merger & Restructuring Charges | - | - | - | - | -9.66 | -2 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | - | -0.41 | - | Upgrade |
Legal Settlements | - | - | - | - | - | 1.5 | Upgrade |
Other Unusual Items | -6.1 | -4.4 | 2.36 | -4.38 | - | - | Upgrade |
Pretax Income | -15.64 | -57.1 | -63.5 | -96.08 | -122.73 | -91.25 | Upgrade |
Income Tax Expense | - | -2.27 | -1.25 | -1.42 | - | -0.11 | Upgrade |
Net Income | -15.64 | -54.84 | -62.26 | -94.66 | -122.73 | -91.14 | Upgrade |
Net Income to Common | -15.64 | -54.84 | -62.26 | -94.66 | -122.73 | -91.14 | Upgrade |
Shares Outstanding (Basic) | 156 | 147 | 138 | 136 | 79 | 43 | Upgrade |
Shares Outstanding (Diluted) | 156 | 147 | 138 | 136 | 79 | 43 | Upgrade |
Shares Change (YoY) | 8.48% | 6.61% | 1.51% | 71.62% | 85.32% | 63.32% | Upgrade |
EPS (Basic) | -0.10 | -0.37 | -0.45 | -0.70 | -1.55 | -2.14 | Upgrade |
EPS (Diluted) | -0.10 | -0.37 | -0.45 | -0.70 | -1.55 | -2.14 | Upgrade |
Free Cash Flow | 9.98 | -37.85 | -49.29 | -103.42 | -96.62 | -80.94 | Upgrade |
Free Cash Flow Per Share | 0.06 | -0.26 | -0.36 | -0.76 | -1.22 | -1.90 | Upgrade |
Gross Margin | 84.56% | 81.86% | 82.52% | 79.47% | 73.14% | 54.35% | Upgrade |
Operating Margin | 5.97% | -13.56% | -26.85% | -74.32% | -212.74% | -399.05% | Upgrade |
Profit Margin | -5.88% | -27.00% | -37.98% | -85.86% | -247.48% | -446.00% | Upgrade |
Free Cash Flow Margin | 3.75% | -18.64% | -30.07% | -93.80% | -194.84% | -396.06% | Upgrade |
EBITDA | 28.04 | -15.48 | -31.68 | -69.7 | -103.62 | -80.08 | Upgrade |
EBITDA Margin | 10.53% | -7.62% | -19.33% | -63.22% | -208.95% | - | Upgrade |
D&A For EBITDA | 12.13 | 12.07 | 12.33 | 12.24 | 1.88 | 1.47 | Upgrade |
EBIT | 15.9 | -27.55 | -44.01 | -81.94 | -105.5 | -81.55 | Upgrade |
EBIT Margin | 5.97% | -13.56% | -26.85% | -74.32% | -212.74% | - | Upgrade |
Revenue as Reported | 266.14 | 203.07 | 163.91 | 110.25 | 49.59 | 20.44 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.